Micafungin ”hikma” (Micafungin)

Micafungin is an echinocandin antifungal used to treat serious Candida infections.

• Invasive candidiasis: effective therapy for bloodstream and deep‑tissue Candida infections in high‑risk patients.
• Candida esophagitis: resolves mucosal infection and associated symptoms in immunocompromised individuals.
• Candida peritonitis: provides targeted treatment for intra‑abdominal Candida infection following surgery or peritoneal dialysis.
• Prophylaxis in hematopoietic stem cell transplant patients: reduces incidence of invasive fungal disease during periods of severe neutropenia.

• Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesizing β‑(1,3)‑D‑glucan, a critical component of the fungal cell wall. Disruption of cell‑wall formation leads to osmotic instability and fungal cell lysis, while human cells lacking this pathway remain unaffected.

Micafungin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Infusion‑related reactions such as flushing, chills or mild hypotension.
• Gastrointestinal upset including nausea or abdominal discomfort.
• Transient elevation of liver enzymes (ALT, AST).

Serious or Rare Side Effects

• Severe hepatic failure or jaundice.
• Anaphylactic or severe hypersensitivity reactions.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Acute renal impairment or oliguria.
• Significant hypotension requiring medical intervention.
• Eosinophilic pneumonia or other rare pulmonary events.

When using Micafungin, clinicians should observe several safety considerations to minimize risk.

• Liver function monitoring: assess baseline and periodic hepatic enzymes during therapy.
• Renal function assessment: evaluate creatinine clearance before and during treatment.
• Hypersensitivity vigilance: discontinue if signs of severe allergic reaction appear.
• Caution in pre‑existing hepatic disease: consider alternative agents or dose adjustment.
• Drug‑specific contraindications: avoid in patients with known hypersensitivity to echinocandins.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines; awareness of the interaction level guides clinical management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may markedly reduce Micafungin exposure.
• Co‑administration with other echinocandins provides no additive benefit and may increase toxicity.
• Known hypersensitivity to other echinocandins should preclude use.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole) may increase hepatic toxicity; monitor liver enzymes.
• Immunosuppressants such as cyclosporine or tacrolimus may require dose adjustment due to potential hepatic effects.
• Moderate CYP inducers (e.g., efavirenz) could lower plasma levels; consider therapeutic drug monitoring.